한글목차

Taiwan Liposome Company(TLC)는 일반적인 마취제인 로피바카인에 서방형 전달 기술을 도입한 속효성, 지속성, 비오피오이드성 수술 후 국소 마취제 TLC590을 개발하고 있으며, 수술 후 통증에 대한 국소 마취의 투여 횟수를 줄이기위한 것입니다.보다 효과적인 진통으로 환자는 수술 후 통증 치료에 자주 사용되는 오피오이드 치료 문제를 피할 수 있습니다.

부피바카인과 로피바카인은 수술 후 통증에 자주 사용되지만 반감기가 비교적 짧다는 문제가 있습니다. 전위 의존성 나트륨 채널을 가역적으로 저해함으로써 통증 관리에 널리 사용되고 있습니다.

이 보고서는 주요 7개국에서 TLC590 시장을 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술후 통증에 있어서의 TLC590의 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 TLC590 시장 평가

• 수술 후 통증에 대한 TLC590 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"TLC590 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about TLC590 for Postoperative pain in the seven major markets. A detailed picture of the TLC590 for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TLC590 for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TLC590 market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

Taiwan Liposome Company (TLC) is developing TLC590, a fast onset, long-lasting, nonopioid postsurgical local anesthetic that brings sustained release delivery technology to the common anesthetic ropivacaine, intending to reduce the frequency of administration for local anesthesia for postsurgical pain. More effective pain relief may also allow patients to avoid the problems of opioid therapies often used to treat postsurgical pain.

Bupivacaine and ropivacaine are frequently used for postsurgical pain; however, they suffer from a relatively short half-life. Ropivacaine, an amino-amide long-acting local anesthesia drug, is widely used in pain management by reversibly inhibiting the voltage-gated sodium channels in nerve fibers. It exhibits reduced cardiotoxicity and CNS toxicity than bupivacaine and is the active drug in TLC590.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the TLC590 description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on TLC590 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TLC590 research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around TLC590.
• The report contains forecasted sales of TLC590 for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for TLC590 in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TLC590 Analytical Perspective by DelveInsight

• In-depth TLC590 Market Assessment

This report provides a detailed market assessment of TLC590 for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• TLC590 Clinical Assessment

The report provides the clinical trials information of TLC590 for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TLC590 dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to TLC590 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TLC590 in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of TLC590 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TLC590 in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of TLC590?
• What is the clinical trial status of the study related to TLC590 in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TLC590 development?
• What are the key designations that have been granted to TLC590 for Postoperative pain?
• What is the forecasted market scenario of TLC590 for Postoperative pain?
• What are the forecasted sales of TLC590 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TLC590 for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. TLC590 Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. TLC590 Market Assessment

• 5.1. Market Outlook of TLC590 in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of TLC590 in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of TLC590 in the United States for Postoperative pain
  • 5.3.2. Market Size of TLC590 in Germany for Postoperative pain
  • 5.3.3. Market Size of TLC590 in France for Postoperative pain
  • 5.3.4. Market Size of TLC590 in Italy for Postoperative pain
  • 5.3.5. Market Size of TLC590 in Spain for Postoperative pain
  • 5.3.6. Market Size of TLC590 in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of TLC590 in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options